AB Science publishes on positive phase 2/3 clinical trial with masitinib in ALS

AB Science SA (NYSE Euronext – FR0010557264 – AB), announces today that full, peer-reviewed results from its phase 2/3 (AB10015) study of masitinib in amyotrophic lateral sclerosis (ALS) have been published in the journal Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (ALSFD).

Entitled, ‘Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial’¹, this article and its accompanying online supplemental material are freely accessible online from the journal website: https://doi.org/10.1080/21678421.2019.1632346.

Study AB10015 reached its primary endpoint and showed that masitinib at 4.5 mg/kg/day in combination with riluzole was able to significantly (p-value < 0.05) slow ALSFRS-R decline by 27% as compared with the active riluzole control at week 48.

https://www.marketscreener.com/AB-SCIENCE-6133795/news/AB-Science-announces-the-publication-of-the-positive-phase-2-3-clinical-trial-with-masitinib-in-ALS-28864666/